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ABSTRACT
Introduction: People living with dementia may
experience and express pain in different ways to people
without dementia. People with dementia are typically
prescribed fewer analgesics than people without
dementia indicating a potential difference in how pain
is identified and treated in these populations. The
objectives of this study are to (1) investigate the
prevalence of analgesic load, pain and daytime
sedation in people with and without dementia in
Australian residential aged care facilities (RACFs), and
(2) investigate the clinical and diagnostic associations
between analgesic load, pain and daytime sedation in
people with and without dementia in Australian RACFs.
Methods/analysis: This will be a cross-sectional
study of 300 permanent residents of up to 10 low-level
and high-level RACFs in South Australia with and
without dementia. Trained study nurses will administer
validated and dementia-specific assessments of self-
reported and clinician-observed pain, sedation and
other clinical and humanistic outcomes. Medicine-use
data will be extracted directly from each resident’s
medication administration chart. Binary and
multinominal logistic regression will be used to
compute unadjusted and adjusted ORs and 95% CIs for
factors associated with pain, analgesic load and daytime
sedation. These factors will include dementia severity,
behavioural and psychological symptoms, quality of life,
resident satisfaction, attitudes towards medicines,
activities of daily living and nutritional status.
Ethics and dissemination: Institutional ethics
approval has been granted. The findings will be
disseminated through public lectures, professional and
scientific conferences and in peer-reviewed journal
articles. The findings of this study will allow for a better
understanding of the prevalence and factors associated
with analgesic use, pain and other outcomes in
residential care. The findings of this study will be used to
inform the development and implementation of strategies
to improve the quality of life of people with dementia.
BACKGROUND
A key objective when offering treatment to
people with Alzheimer’s disease (AD) and
other dementias is to alleviate suffering and
maintain quality of life. Pain is common
among residents of residential aged care
facilities (RACFs) with and without demen-
tia.1 2 The way that people with dementia
experience and express pain is a topic of
ongoing research.3
People with AD may communicate pain
non-verbally via facial expressions, body
movements and behavioural disturbances.
These pain signs may go unrecognised and
therefore not prompt clinicians to prescribe
analgesic medicines.1 3 Most previous studies
have reported lower overall use of analgesics
Strengths and limitations of this study
▪ A broad range of outcomes and risk factors will
be assessed, thus allowing for the generation
and exploration of a range of hypotheses. The
additional prospective collection of hospitalisa-
tion and mortality data will enable an exploration
of the effect of pain, analgesia and other covari-
ates on the development of these outcomes.
▪ The findings of this research will enable a better
understanding of the prescribing practices in
aged care facilities and will assist in the develop-
ment of targeted pain management services for
people with dementia.
▪ The cross-sectional study design means it is dif-
ficult to make causal inferences about the data.
Although the study will involve multiple aged
care facilities, the generalisability may be limited.
As with all observational studies, there will be
the possibility of confounding.
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in people with dementia compared with those without
dementia and hypothesised that this may reﬂect
untreated pain in these people.4–6 Untreated pain has
been associated with increased use of healthcare and
aggression.7 8 Use of analgesic medicines has been asso-
ciated with higher quality of life in people with demen-
tia.9 Pain-related behavioural disturbances may also be
misinterpreted as behavioural and psychological symp-
toms of dementia leading to inappropriate prescription
of psychotropic medicines which have been associated
with impaired cognition, falls and fractures and
increased risk of death.10 11
Clinicians working in RACFs are faced with the need
to alleviate pain while minimising daytime sedation and
prescription of psychotropic medicines. Medicine selec-
tion is also challenging as older people have a high
prevalence of multimorbidity, frailty, polypharmacy and
increased susceptibility to adverse drug events
(ADEs).12–14 The lower prevalence of analgesic use
among people with dementia may be partly linked to
fear of ADEs (eg, excess sedation, falls and fractures,
delirium and respiratory depression) as well as non-
recognition of pain.15–17 A cluster randomised con-
trolled trial has demonstrated that a systematic approach
to pain management, using a stepwise protocol for anal-
gesic use, reduced agitation in aged care facility resi-
dents.18 This ﬁnding suggests that improved recognition
and treatment of pain may be an effective strategy to
reduce the unnecessary use of sedative and psychotropic
medicines among residents of aged care facilities.
The aims of this study are to (1) investigate the preva-
lence of analgesic load, pain and daytime sedation in
people with and without dementia in Australian RACFs
and (2) investigate the clinical and diagnostic correlates
of analgesic load, pain and daytime sedation in people
with and without dementia in Australian RACFs.
METHODS
Design and setting
This will be a cross-sectional study among permanent
residents of up to 10 low-level or high-level RACFs in
South Australia. These RACFs will be located in metro-
politan Adelaide (population 1.2 million) and Mt
Gambier (population 25 000). Adelaide is the state
capital city and the ﬁfth most populous city in Australia.
Mt Gambier is a regional centre located approximately
450 km south of Adelaide. The aged care facilities will
be approached to participate via one provider of aged
care in South Australia.
Consumer involvement
The project will be conducted in accordance with
Alzheimer’s Australia guidelines for involving people
living with dementia and their families in research
(Alzheimer’s Australia, 2013). The investigative team
includes a member of the Alzheimer’s Australia
Consumer Dementia Research Network (TQ). The
member of the Consumer Dementia Research Network
has reviewed all project proposals from a consumer per-
spective, will participate on the project advisory commit-
tee and will assist in dissemination of the ﬁndings.
Participants
Permanent residents of low-level or high-level care
RACFs will be invited to participate by a trained study
nurse. This will include residents with and without
dementia. Inclusion criteria will be age 65 years or older
and ability to participate in structured assessments in
English. Residents may be excluded at the discretion of
RACF staff and their treating clinicians. Residents
deemed by facility staff to be medically unstable (eg,
experiencing delirium) or estimated by facility staff to
have less than 3 months to live will be excluded from
participation.
Data collection
Data will be collected using a standard data extraction
form comprising a series of validated and widely used
scales. The choice of scales was consistent with those
included in the Dementia Management Outcomes Suite
of the Australian Government Dementia Collaborative
Research Centres. Data will be collected by experienced
nurses employed by the participating aged care provider.
Where possible, data will be collected by the same
nurses at each RACF. Study nurses will undergo training
in a centralised location in the standard administration
of the study assessment tools. All nurses involved in the
data collection will have undergone the mandatory
police clearances for working with older people. The
concordance between assessments performed by differ-
ent study nurses will be established for an initial sub-
sample of residents at one RACF. If required, each
resident’s general medical practitioner or community
pharmacist may be contacted to provide additional data
relevant to the study outcomes. For scales requiring
input of a staff informant, staff informants will be
required to have known the resident for at least 2 weeks.
If during the data collection process a study nurse iden-
tiﬁes a sign or symptom requiring medical attention, this
will be brought to the attention of the care coordinator




Two validated pain scales suitable for use among people
with dementia will be used. This will include a
dementia-speciﬁc, clinician-administered observational
scale (Pain Assessment in Advanced Dementia
(PAINAD) Scale) and a resident self-report scale
(FACES Pain Scale Revised (FPS-R)). The resident self-
report scale will be used in addition to the observational
scale because observational scales may underestimate
pain in people with dementia.6 19 The scales will be
administered when each resident is at rest.
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The PAINAD Scale is a ﬁve-item clinician-administered
observational scale with domains related to breathing,
negative vocalisation, facial expressions, body language
and consolability.20 Possible scores range from 0 to 10,
with higher scores indicating more severe pain. The
scale will be administered after observing the resident
for 5 min. The FPS-R is designed for people who are
able to self-report but may be unable to use a traditional
numeric rating scale.21 The scale consists of six faces
that show how much pain or discomfort someone is
feeling. The face on the left shows no pain whereas the
face on the right shows the worst pain possible. The
scale is scored from 0 ‘no pain’ to 10 ‘worst pain pos-
sible’. Using the FPS has been demonstrated to be feas-
ible and more easily understood than a traditional
horizontal Visual Analogue Scale in people with a
Mini-Mental State Examination (MMSE) score less than
11 and a Clinical Dementia Rating score of 3.19
Medicine use and analgesic load
Medicine-use data from the previous 24 h will be
extracted directly from each resident’s medication
administration chart by a study nurse. This will include
prescription medicines, non-prescription medicines, vita-
mins and minerals and complementary and alternative
medicines administered regularly and as required. The
medicine name, strength, number of doses and whether
it was administered will be recorded. This means that
medicine-use data will represent each resident’s actual
use rather than their prescribed or intended pattern of
use. Prescription and non-prescription medicines taken
by the residents will be classiﬁed using the Anatomical
Therapeutic Chemical (ATC) classiﬁcation system
recommended by the WHO.22
Analgesics will be deﬁned as paracetamol (N02BE),
non-steroidal anti-inﬂammatory drugs (ATC codes
M01AB-H, M01AX01, M02AA, M02AC, N02BA) and
opioids (N02A). Opioids will be subclassiﬁed as strong
and weak opioids. Low-dose (≤250 mg/day) aspirin will
not be classiﬁed as an analgesic because it is primarily
used as an antiplatelet. Analgesic load will be calculated
according to a previously published model developed in
the USA.23 To calculate each resident’s analgesic load,
analgesic ratings will be assigned to each medicine taken
by each resident on a regular or as-needed basis.
▸ Opioids for the treatment of moderate-to-severe pain
(analgesic rating 9, eg, morphine, fentanyl).
▸ Opioids for the treatment of mild-to-moderate pain
(analgesic rating 6, eg, tramadol).
▸ Non-opioid analgesics (analgesic rating 3, eg, ibupro-
fen, celecoxib).
▸ Adjuvant medicines (analgesic rating 1, eg, valproate,
sertraline).
▸ Non-analgesic medicines (analgesic rating 0).
For each analgesic, a score will be derived by multiply-
ing the daily dose by the analgesic rating and dividing
by the average daily maintenance dose. The scores for
each analgesic will be summed to compute each resi-
dent’s analgesic load.
Sedative load resulting from each resident’s exposure
to medicines with sedative properties will be computed
using a published model.24 This model considers medi-
cines prescribed for sedation, medicines with sedation as
a prominent side-effect and medicines with a sedating
component.
Daytime sedation
Daytime sedation will be assessed using a clinician-
administered observational scale (Pasero Opioid-induced
Sedation Scale (POSS)) and a resident self-report scale
(Epworth Sleepiness Scale (ESS)). The POSS is a ﬁve-item
clinician-rated scale.25 The reliability and validity of the
POSS has been demonstrated for measuring sedation
during administration of opioids.26 The ESS is a widely
used eight-item resident self-report scale. Respondents are
asked to rate their chance of falling asleep in eight differ-
ent situations on a four-point scale. The ESS has been
used among people with AD,27 and to assess the contribu-
tion of medicines to daytime sedation.28 The scale has also
been successfully used previously in the hostel setting.29
Sleep quality will also be assessed using a previously vali-
dated six-item questionnaire. Three questions pertain to
night-time sleep behaviour, including overall sleep quality,
sleeping duration and restfulness. Other questions address
alertness in the mornings and the frequency and duration
of daytime napping.30
Covariates and secondary outcomes
Dementia severity
The Dementia Severity Rating Scale (DSRS) will be used
to assess the severity of each resident’s dementia. This is
a 12-item scale designed to be completed in consultation
with a staff informant.31 It has been demonstrated to be
a valid, reliable and sensitive measure of impairment
associated with AD.31 Enrolled or registered nurses will
complete the scale.
Behavioural and psychological symptoms
Behavioural and psychological symptoms common in
dementia will be assessed using the Neuropsychiatric
Inventory Nursing Home version (NPI-NH).32 The
NPI-NH contains the same 12 domains as the original
NPI,33 but has been reworded to allow for completion in
consultation with staff informants who did not know the
resident prior to the onset of illness. The NPI-NH has
domains related to delusions, hallucinations, aggression/
agitation, depression/dysphoria, anxiety, elation/euphoria,
apathy/indifference, disinhibition, irritability/lability and
aberrant motor behaviour, sleep and night-time behaviour
disorders and appetite and eating disorders.
Quality of life
Each resident’s quality of life will be assessed by a regis-
tered or enrolled nurse using the staff informant version
of the 15-item Quality of Life in Alzheimer’s Disease
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Scale (QoL-AD). The 15-item version for use in RACFs
is an adaption of the original 13-item version for use
among community-dwelling people with dementia.34
Previous research suggests the QoL-AD scale has good
validity and reliability when used for people with demen-
tia with MMSE scores greater than 10.35 In a recent
study, the 15-item QoL-AD scale was successfully com-
pleted by 64% of residents with dementia in West
Australian RACFs.36
Attitudes towards medicine regimen
Residents’ attitudes towards medicines will be assessed
using the 10-item Patients’ Attitudes Towards
Deprescribing (PATD) questionnaire.37 The PATD has
satisfactory criterion validity and test–retest reliability
when used in general adult samples. The PATD will be
interviewer administered by the study nurse. The face
validity of the PATD in people with dementia will be
assessed prior to use.
Resident satisfaction
Resident satisfaction will be assessed using Hawthorne’s
revised 7-item Short Assessment of Patient Satisfaction
(SAPS).38 Residents will be asked questions in relation to
their overall care at the facilities, with an emphasis on
interactions with nursing staff and carers.
Other clinical factors
Each resident’s nutritional status will be assessed using
the Mini Nutritional Assessment Short Form
(MNA-SF).39 The MNA-SF has been validated as an
assessment tool for evaluating malnutrition in elderly
people.39 40 Nutritional status has been associated with
polypharmacy and is strongly predictive of poor progno-
sis in residents of aged care facilities.41 Activities of daily
living will be assessed using the Katz Activities of Daily
Living (ADL) scale.42 This six-item scale includes
domains related to bathing, dressing, toileting, transfer-
ring, continence and feeding. Diagnostic data will be
extracted directly from each resident’s electronic case
notes and be used to compute a range of comorbidity
indices including the Functional Comorbidity Index
(FCI).43
Hospitalisation and mortality
RACF records will be used to determine the number,
reasons for and duration of days in hospital over a
36-month period following the cross-sectional data col-
lection. Data on deaths that occur over a 36-month
period following the cross-sectional data collection will
be obtained from the Consumer and Business Services:
Births, Deaths and Marriages, South Australia.
Hospitalisation and mortality data will be investigated
because a previous study has suggested that potentially
inappropriate medicine use deﬁned using Beers criteria
is associated with increased hospitalisation and mortality
among residents of aged care facilities.44
Sample size and statistical analyses
Assuming a power of 80%, a two-sided level of signiﬁ-
cance of 0.05, dementia prevalence of 50%45 46 and an
analgesic prevalence of 60%,46 a sample size of 258 par-
ticipants would be required to detect a signiﬁcant preva-
lence ratio (PR) of 0.7 in our primary outcome of
analgesic use (OpenEpi V.2.3.1). To maintain adequate
power in multivariate analyses, an approximate sample
size of 5–20 cases is required per adjustment variable.
For this reason, we will aim to recruit up to 300 residents
with and without dementia to allow our analyses to be
adjusted for a range of clinically important covariates.
This sample size is consistent with similar cohort studies
investigating quality of life and neuropsychiatric symp-
toms in people with dementia in Australia and
internationally.36 47
Regression analyses will be performed to compute
unadjusted and adjusted ORs and 95% CIs for the asso-
ciation between pain, analgesic load and daytime sed-
ation in people with AD and other dementias. The ORs
will be transformed to PRs when outcomes are more
common than 10%.48 Multiple imputation will be used
to impute missing covariate values where applicable.
This has been demonstrated to be superior complete
case analyses when data are missing at random.49
Analyses will be adjusted for age, sex, medicine use (eg,
sedative load), diagnoses and other clinically relevant
covariates. In addition to standard reporting in tables
and ﬁgures, results will also be presented as three-
dimensional, geometric frameworks to provide a visual
representation.50 Analyses will be undertaken using the
Statistical Package for the Social Sciences (SPSS, V.17.0,
Chicago, Illinois, USA).
Ethical considerations
A study nurse employed by the aged care provider will
be responsible for inviting each resident to participate
in the project. All potential resident participants will be
provided with verbal and written information about the
study. This will be carried out in accordance with the
ethical principles for involving people with cognitive
impairment in research studies that are outlined in the
Australian National Statement for Ethical Conduct in
Human Research.51 Consent to participate will be
obtained from the residents if they have the capacity to
consent. In cases where residents are unable to provide
written informed consent themselves, consent to partici-
pate will be sought from their guardian, next of kin or
signiﬁcant other. Residents with an enduring power of
guardianship will be identiﬁed by the participating aged
care provider. In these cases, the study nurse will still
explain to the resident, as much as possible, what partici-
pation will involve and consent will be sought from the
guardian. All data will be treated conﬁdentially and in
accordance with Australian regulations. Data will be
stored in a locked cabinet at the Centre for Medicine
Use and Safety, Faculty of Pharmacy and Pharmaceutical
Sciences, Monash University for a minimum of 5 years.
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The study will be conducted in accordance with the
World Medical Association (WMA) Declaration of
Helsinki.
Dissemination of research findings
The ﬁndings will be communicated to consumers and
carers at one or more public lectures, with consumers
and carers involved in the preparation and delivery of
the lecture. The results will be presented at professional
and scientiﬁc conferences. The results will also be disse-
minated in peer-reviewed scientiﬁc journal articles. All
clinicians and RACFs that participate in the research will
be provided with a copy of the ﬁnal report, which will
include a lay summary of the ﬁndings.
DISCUSSION
This study aims to improve pain management and, in
turn, the quality of life of residents of RACFs with
dementia. It will investigate outcomes that are important
to consumers, and will involve close liaison with consu-
mers, carers and clinicians throughout the study. The
cross-sectional study design will enable the investigation
of the prevalence of analgesic use, pain, sedation and
other outcomes and the factors associated with these
outcomes in residents of RACFs. Several different out-
comes and risk factors will be assessed, thus allowing for
the generation and exploration of a range of hypoth-
eses. The additional prospective collection of hospitalisa-
tion and mortality data will enable an exploration of the
effect of pain, analgesia and other covariates on the
development of these outcomes. The ﬁndings of this
research will enable a better understanding of the pre-
scribing practices in RACFs and will assist in the develop-
ment of targeted pain management services for people
with dementia.
Limitations
The cross-sectional study design means it is difﬁcult to
make causal inferences about the data. Generalisability
may be limited to the sampled population, and ﬁndings
may not be applicable to all older people or other set-
tings. Selection bias may occur, with volunteer bias being
a potential limitation. Residents and families choosing
to participate in the study may tend to be those who are
healthier, have less cognitive impairment or are more
involved in their pain management. These issues will be
minimised by ensuring a census sample of eligible resi-
dents is recruited from each facility where possible.
Additionally, demographics of the participants will be
compared with all residents of the RACF to assess repre-
sentativeness of the sample. Close engagement and
monitoring by the research team will ensure that recruit-
ment and data collection protocols are implemented
consistently.
CONCLUSION
This study will investigate the association between medi-
cation use and clinical characteristics in residents with
and without dementia in RACFs. The ﬁndings of this
study will allow for a better understanding of the preva-
lence and risk factors associated with analgesic use, pain,
sedation and other outcomes in aged care settings. This
will help guide the development and implementation of
strategies to improve the quality of life of people with
dementia.
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